Work

COLUMBUS–Essai de phase III randomisé évaluant encorafénib (enco) + binimétinib (bini) vs vémurafénib (vému) ou enco chez des patients atteints d’un mélanome avec mutation BRAF V600. Actualisation des données à 7 ans

Year: 2023

Type: article

Source: Annales de Dermatologie et de Vénéréologie - FMC

DOI: 10.1016/j.fander.2023.09.577

Authors: C. Robert, D. Schadendorf, R. Dummer, K.T. Flaherty, A. Arance, J.W. De Groot, C. Garbe, H.J. Gogas, R. Gutzmer, I. Krajsová, L. Gabriella, L. Carmen, M. Mandala, Y. Naoya, G. Carolin, P.A. Ascierto

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, University Hospital Zurich, Massachusetts General Hospital, Hospital Clínic de Barcelona, Isala, University of Tübingen, National and Kapodistrian University of Athens, Medizinische Hochschule Hannover, Charles University, National Institute of Oncology, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, University of Perugia, Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Institut Cochin, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Language: French

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4388782013

FWCI:

Cites:

Cited by:

Related to: 10